Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at politicsandmyportfolio.com, will continue to monitor these healthtech companies to see if the momentum continues. PoliticsAndMyPortfolio.com is looking into these tickers DAWN, MTDR, AVY, CMC, MNST, RTX and more..
Recent SEMHF Stock Price: $48.20
Summary: N/A
Richard Felton analyst at Goldman Sachs reiterates coverage on Siemens Healthineers AG (SEMHF) stock in the energy sector with a Hold rating and has set SEMHF's stock price target at $57.47.
TipRanks.com reports that Siemens Healthineers AG currently has 5 analysts offering 12-month price targets on SEMHF and the consensus is a Strong Buy rating with an average stock price target of $62.52. The most recent SEMHF stock price we have is $48.20 and we are not making any SEMHF forecasts at this time.
In addition, TradingView issued a strong sell rating for SEMHF over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on SEMHF. politicsandmyportfolio.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on SEMHF, please click here >>
Immunovant, IMVT
Recent IMVT Stock Price: $39.96
Summary: Immunovant, Inc. is a clinical-stage biopharmaceutical company, which develops monoclonal antibodies for the treatment of autoimmune diseases. It is developing batoclimab, a novel, fully-human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company is developing batoclimabas a fixed-dose subcutaneous injection for the treatment of autoimmune diseases. It's developing batoclimab with an initial focus on the treatment of myasthenia gravis, an autoimmune disease; thyroid eye disease; and warm autoimmune hemolyticanemia. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd. (RSL). Roivant Sciences GmbH (RSG), a wholly-owned subsidiary of RSL, entered into the HanAll agreement. Per the agreement, RSG received the non-exclusive right to manufacture and exclusively develop, import and use batoclimaband commercialize it in the United States, the EU during the term of the agreement.
Danielle Brill analyst at Raymond James reiterates coverage on Immunovant (IMVT) stock in the energy sector with a Buy rating and has set IMVT's stock price target at $40.
TipRanks.com reports that Immunovant currently has 5 analysts offering 12-month price targets on IMVT and the consensus is a Strong Buy rating with an average stock price target of $37.40. The most recent IMVT stock price we have is $39.96 and we are not making any IMVT forecasts at this time.
In addition, TradingView issued a Strong buy rating for IMVT over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on IMVT. politicsandmyportfolio.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on IMVT, please click here >>
Intercept Pharma, ICPT
Recent ICPT Stock Price: $18.71
Summary: Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing novel therapeutics to treat chronic liver diseases to market. The company's focus is on treating orphan and more prevalent liver diseases with limited treatment options. The company received FDA approval for Ocaliva an farnesoid X receptor against in combination with ursodeoxycholic acid, for the treatment of primary biliary cholangitis in adults with an inadequate response to UDCA or as monotherapy in adults who are intolerant to UDCA. Ocaliva was approved in the EU for the same indication. The drug was approved in Canada. OCA is also being developed for additional indications like primary sclerosing cholangitis and non-alcoholic steatohepatitis. The FDA accepted its New Drug Application for OCA seeking accelerated approval for the treatment of fibrosis due to NASH. Intercept received a complete response letter from the FDA stating that its NDA for OCA for the treatment of liver fibrosis due to NASH could not be approved.
Edward Nash analyst at Canaccord Genuity reiterates coverage on Intercept Pharma (ICPT) stock in the energy sector with a Hold rating and has set ICPT's stock price target at $19.
TipRanks.com reports that Intercept Pharma currently has 4 analysts offering 12-month price targets on ICPT and the consensus is a Hold rating with an average stock price target of $17.25. The most recent ICPT stock price we have is $18.71 and we are not making any ICPT forecasts at this time.
In addition, TradingView issued a Strong buy rating for ICPT over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on ICPT. politicsandmyportfolio.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on ICPT, please click here >>
The editors at politicsandmyportfolio.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
PoliticsAndMyPortfolio.com keeps our subscribers informed of breaking news, reports, stock news or information that can have a positive or negative impact on their portfolio. We look at world events, political activity and the movement of stocks, bonds, metals, commodities and more to provide investors with timely information. Join thousands of investors who already signed up for our free subscription to PoliticsAndMyPortfolio.com.
==============================================================================
